Compare SON & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SON | TVTX |
|---|---|---|
| Founded | 1899 | N/A |
| Country | United States | United States |
| Employees | N/A | 497 |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2014 | 2013 |
| Metric | SON | TVTX |
|---|---|---|
| Price | $49.56 | $44.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 13 |
| Target Price | ★ $60.13 | $40.62 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.39% | N/A |
| EPS Growth | ★ 510.30 | 92.89 |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $7,518,753,000.00 | N/A |
| Revenue This Year | $0.10 | $44.76 |
| Revenue Next Year | $1.82 | $35.51 |
| P/E Ratio | $71.64 | ★ N/A |
| Revenue Growth | ★ 41.72 | N/A |
| 52 Week Low | $38.65 | $13.88 |
| 52 Week High | $58.44 | $48.61 |
| Indicator | SON | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.93 | 61.88 |
| Support Level | $46.73 | $41.55 |
| Resistance Level | $52.71 | $48.61 |
| Average True Range (ATR) | 1.32 | 2.22 |
| MACD | -0.02 | -0.34 |
| Stochastic Oscillator | 52.57 | 43.35 |
Sonoco Products Co is engaged in the manufacture and supply of consumer and industrial packaging products, offering paper, metal, and plastic packaging solutions across multiple end markets. The company has two reportable segments: Consumer Packaging and Industrial Paper Packaging. The Consumer Packaging segment provides rigid packaging solutions mainly for food, beverage, household, personal care, and pharmaceutical products, while the Industrial Paper Packaging segment produces paper-based packaging materials such as tubes, cores, and protective packaging, supported by paper mills and recycling operations, serving industrial and consumer markets. It generates the majority of its revenue from the Consumer Packaging segment.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.